Extended Data Fig. 8: Patient-specific CAR T cell responses in donor matched leukaemia chips.
(a) Donor matched leukaemia chip study using three matched patient samples (PD7606, PD7813, and PD8012 bone marrow mononuclear cells and matched PD7607, PD7814, and PD8009 peripheral blood mononuclear cells, respectively). (b,c) The whole scanning (top left), 3D view (top right), and 2D view (bottom) of patient-specific bone marrow niches on-chip built with bone marrow mononuclear cells from donors PD7813 (b) and PD8012 (c) after 5-day on-chip culture. Representative images were from one of three technical replicates with similar results (n = 3). (d) Representative images of surface expression of CD69 on CAR T cells from chips prepared with healthy donor-derived bone marrow mononuclear cells, corresponding to Fig. 6c. Representative data from three technical replicates with similar results (n = 3). (e) ELISA measured secretions of granzyme B from patient-specific leukemia chips treated with donor-matched CAR T cell (CAR) and Mock T cell (Mock) at different time points (day 0, 2, 5, and 7). Data was collected from 3 technical replicates (n = 3). Two-way ANOVA followed by Tukey’s post hoc test, mean and s.e.m. (f) Cytokine secretion profiles of different matched patient-derived 4-1BBζ-CAR T cells on-chip (dose of 10,000 CAR T cells) on day 2 were examined by using a Human Inflammation Array C3 membrane kit. Data was mean of two technical replicates (n = 2).
